Literature DB >> 26850987

Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade.

Ranjan Preet1, Sumit Siddharth1, Shakti Ranjan Satapathy1, Sarita Das1, Anmada Nayak1, Dipon Das1, Michael D Wyatt2, Chanakya Nath Kundu3.   

Abstract

Quinacrine (QC) causes apoptosis in breast cancer cells by induction of DNA damage, arrest of cells in S-phase, and by topoisomerase inhibition. Here, we show that QC-mediated apoptosis is not only due to increased DNA damage but also by compromising cell cycle checkpoints and base excision repair (BER) capacity in breast cancer cells. QC decreased CHK1, CDKs (CDC2, MDM2, CDC6), cyclins (B1, E1) and CDC25-A in a dose dependent manner. The expression of basal ATR remains unaltered but pATR (Ser-428) increased after QC treatment. A CHK1 inhibitor, SB218078, was also tested alone and in combination with QC. Like QC, SB218078 caused apoptosis by DNA damage and S-phase arrest. The combination of QC and SB218078 increased apoptosis by blocking the cell cycle in G2/M, which caused a mitotic catastrophe, and induced DNA damage at a higher level in comparison to individual compound treatments. Both drugs individually or in combination decreased the levels of replication protein A (RPA). Measurement of the expression of BER (SP- and LP-BER) proteins and direct in vivo BER activity revealed that the QC/SB218078 combination caused apoptosis in cancer cells by disrupting the induction of BER, which represents a novel means of potentially treating breast cancer.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  9-Aminoacridine; Base-excision repair; Breast cancer; CHK1; Quinacrine

Mesh:

Substances:

Year:  2016        PMID: 26850987     DOI: 10.1016/j.bcp.2016.01.017

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  TRAIL enhances quinacrine-mediated apoptosis in breast cancer cells through induction of autophagy via modulation of p21 and DR5 interactions.

Authors:  Sarita Das; Anmada Nayak; Sumit Siddharth; Deepika Nayak; Satya Narayan; Chanakya Nath Kundu
Journal:  Cell Oncol (Dordr)       Date:  2017-09-21       Impact factor: 6.730

2.  Calf Thymus DNA Exposed to Quinacrine at Physiological Temperatures and pH Acquires Immunogenicity: A Threat for Long Term Quinacrine Therapy.

Authors:  Kumari Suganthy Asha; Safia Habib; Shahid Ali Siddiqui; Asif Ali
Journal:  Indian J Clin Biochem       Date:  2021-10-20

Review 3.  ATR/CHK1 inhibitors and cancer therapy.

Authors:  Zhaojun Qiu; Nancy L Oleinick; Junran Zhang
Journal:  Radiother Oncol       Date:  2017-10-18       Impact factor: 6.280

4.  Chitosan-Dextran sulfate coated doxorubicin loaded PLGA-PVA-nanoparticles caused apoptosis in doxorubicin resistance breast cancer cells through induction of DNA damage.

Authors:  Sumit Siddharth; Anmada Nayak; Deepika Nayak; Birendra Kumar Bindhani; Chanakya Nath Kundu
Journal:  Sci Rep       Date:  2017-05-19       Impact factor: 4.379

5.  Vorinostat and quinacrine have synergistic effects in T-cell acute lymphoblastic leukemia through reactive oxygen species increase and mitophagy inhibition.

Authors:  Bo Jing; Jin Jin; Rufang Xiang; Meng Liu; Li Yang; Yin Tong; Xinhua Xiao; Hu Lei; Wei Liu; Hanzhang Xu; Jiong Deng; Li Zhou; Yingli Wu
Journal:  Cell Death Dis       Date:  2018-05-22       Impact factor: 8.469

Review 6.  Overcoming cancer therapeutic bottleneck by drug repurposing.

Authors:  Zhe Zhang; Li Zhou; Na Xie; Edouard C Nice; Tao Zhang; Yongping Cui; Canhua Huang
Journal:  Signal Transduct Target Ther       Date:  2020-07-02

7.  DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt's lymphoma.

Authors:  Candace J Poole; Wenli Zheng; Atul Lodh; Aleksey Yevtodiyenko; Daniel Liefwalker; Honglin Li; Dean W Felsher; Jan van Riggelen
Journal:  Oncotarget       Date:  2017-08-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.